SEC Tracker
Get the app
LCTX · XBRL financial data

Lineage Cell Therapeutics financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (LCTX's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue1,2462,0881,4441,4083,7792,868*1,5022,7653,6816,608*1,7251,069
Revenue from contracts with customers1,2462,088*1,4441,4083,7792,868*1,5022,7653,6816,608*1,7251,069
Cost of revenue169256*984438154*36—————
Gross profit1,0771,832*———2,714*——————
Research and development3,7413,906*3,0102,8683,1713,423*3,1143,1063,2718,238*4,2344,774
General and administrative4,0414,288*4,9974,3634,4104,401*4,8574,5604,1914,852*5,0845,218
Total operating expenses7,7828,194——————————
Operating income (loss)(6,705)(6,362)(6,661)(5,867)(3,840)(5,110)*(6,505)(19,780)(3,786)(6,548)*(7,593)(8,923)
Other income (expense)(826)1,249*0190(689)*(185)26027*1(18)
Income tax expense (benefit)00*0000*———year only——
Net income (loss)(7,110)(4,775)(6,542)(5,760)(3,034)(3,273)*(4,139)(30,464)(29,781)851*(4,812)1,482
Earnings per share, basic USD per share(0.04)(0.03)(0.04)(0.03)(0.02)(0.01)*(0.02)(0.13)(0.13)0.00*(0.02)0.01
Earnings per share, diluted USD per share(0.04)(0.03)(0.04)(0.03)(0.02)(0.01)*(0.02)(0.13)(0.13)0.00*(0.03)(0.03)
Weighted average shares, basic thousands of shares174,868174,987*182,909188,813188,835239,903*226,054228,356228,853237,094*245,029249,499
Weighted average shares, diluted thousands of shares174,868174,987*182,909188,813188,835239,903*226,054228,356228,853237,094*261,175261,471

Balance sheet

CSV

Fiscal quarters (LCTX's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents31,47435,44243,57629,62227,75045,78947,88642,27140,46340,79135,93937,355
Marketable securities9,85850458,8744,9612,01619172314,99017,44213,474
Accounts receivable43274577235405638213256127891806790
Prepaid and other current assets1,7172,2042,0181,6591,2852,5541,8661,3001,6472,4851,9771,351
Total current assets43,48138,44145,71640,39034,40150,99749,98443,84442,26059,15756,16452,970
Property and equipment, net4,8544,7672,1042,0182,0132,2512,1492,2552,1572,5662,4972,517
Right-of-use asset—2,5222,8552,5842,3622,1441,9041,8172,3112,1312,1271,964
Goodwill10,67210,67210,67210,67210,67210,67210,67210,67210,67210,67210,67210,672
Total assets106,153101,019108,483102,80296,594113,218111,75390,79989,639112,584109,533106,220
Accounts payable2,4302,0502,2112,3881,5991,1741,9951,4971,5202,3411,5911,536
Accrued liabilities3491,0979914143841,1979027934861,0961,2341,002
Total current liabilities15,88117,96016,89015,27513,86413,97713,08910,7569,38211,3678,1488,016
Lease liability, non-current2,0471,9792,0741,7681,5331,2951,0131,0581,5151,5341,5071,333
Total liabilities39,49338,99637,49335,92731,80036,20634,09843,68768,84369,23856,83846,422
Accumulated deficit(380,081)(384,856)(391,398)(397,158)(400,192)(403,465)(407,604)(438,068)(467,849)(466,998)(471,810)(470,328)
Total stockholders' equity68,11763,41972,40268,30066,18678,38179,02848,38522,04044,54953,87560,916
Total liabilities and equity106,153101,019108,483102,80296,594113,218111,75390,79989,639112,584109,533106,220
Common shares outstanding (cover page) thousands of shares174,987188,534188,798188,837188,837228,356228,356228,356230,328249,088249,298252,907

Cash flows

CSV

Fiscal quarters (LCTX's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(7,110)(4,775)(6,542)(5,760)(3,034)(3,273)*(4,139)(30,464)(29,781)851*(4,812)1,482
Stock-based compensation1,2691,060*1,1631,269*1,330*1,315*1,2171,238*1,199*1,098*1,1721,601*
Depreciation and amortization143*———————————
Net cash from operating activities(5,037)*(6,019)*(5,783)(5,176)*(5,787)*(6,346)*(4,886)(5,539)*(3,616)*(4,878)*(8,078)(7,244)*
Purchases of property and equipment139*91*3850*112*365*9714*12*399*55108*
Net cash from investing activities2,122*9,742*(38)(8,793)*3,888*2,635*1,903(14)*(12)*(15,334)*(2,326)3,960*
Proceeds from issuing common stock836*0*14,03733*0*———————
Net cash from financing activities807*(13)*14,021105*(3)*21,734*5,044(307)*1,834*20,379*5,5614,466*
Net change in cash(2,448)*3,992*8,130(13,952)*(1,864)*18,048*1,988(5,567)*(1,798)*347*(4,848)1,441*

Compare with peers

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Lineage Cell Therapeutics37,3551,069(7,244)*252.9M7.0 quarters 10-QJun 30, 2026
Forte Biosciences49,629not reported(22,702)*21.2M8.7 quarters 10-QJun 30, 2026
4D Molecular Therapeutics70,3723,781(69,999)*55.2M5.2 quarters 10-QJun 30, 2026
Monopar Therapeutics52,7580*(3,247)*6.7M32.4 quarters 10-QJun 30, 2026
XOMA Royalty85,60012,3186,12112.5M— 10-QMar 31, 2026
Lexicon Pharmaceuticals40,924692(9,192)*445.0M20.7 quarters 10-QJun 30, 2026
Sangamo Therapeutics27,5861,442(19,282)414.3M1.4 quarters 10-QMar 31, 2026
Omeros1,98828,5294,149*72.4M— 10-QJun 30, 2026
Alpha Cognition41,3846,093(6,859)*21.8M6.0 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.